Dyne Therapeutics Prepares for Potential Neuromuscular Medicine Launches

Company to Present Clinical Data at AMCP Conference to Contextualize Benefits for Managed Care Experts

Apr. 2, 2026 at 1:04am

Got story updates? Submit your updates here. ›

Dyne Therapeutics, a clinical-stage company focused on genetically driven neuromuscular diseases, announced it will present three posters at the upcoming AMCP 2026 Annual Conference. The posters will cover previously reported positive results from the DELIVER trial in Duchenne muscular dystrophy (DMD) and the ACHIEVE trial in myotonic dystrophy type 1 (DM1), as well as research on health insurance literacy in DM1. The company is preparing for potential launches of its investigational therapies for DMD and DM1 in the coming years.

Why it matters

As Dyne Therapeutics prepares for potential launches of its neuromuscular disease treatments, the company is proactively engaging with payers to ensure access decisions reflect the meaningful benefits seen in clinical trials. The data being presented at AMCP aims to contextualize the functional improvements observed and how they could translate to patients' everyday lives.

The details

The posters will cover previously reported positive results from Dyne's DELIVER trial in Duchenne muscular dystrophy (DMD) and ACHIEVE trial in myotonic dystrophy type 1 (DM1). The DMD poster will focus on how the investigational therapy zeleciment rostudirsen targets the underlying cause of the disease to enable sustained functional improvement. The DM1 posters will cover the investigational therapy zeleciment basivarsen as well as research on health insurance literacy in the DM1 patient community, developed in collaboration with the Myotonic Dystrophy Foundation.

  • Dyne is preparing for a potential DMD launch in the US next year.
  • Dyne is preparing for a potential DM1 launch in early 2028.

The players

Dyne Therapeutics

A clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.

Johanna Friedl-Naderer

Chief commercial officer of Dyne Therapeutics.

Myotonic Dystrophy Foundation (MDF)

A non-profit organization that collaborated with Dyne on the study design and interpretation of results for the DM1 health insurance and literacy poster.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited for a potential DMD launch in the US next year, followed by a potential launch in DM1 in early 2028. As part of the preparations for those two launches, we are engaging with payers now and elucidating how the clinical measures of functional improvement seen in our DELIVER and ACHIEVE trials could translate into meaningful benefits in patients' everyday lives.”

— Johanna Friedl-Naderer, Chief commercial officer

What’s next

Dyne is supporting a continuing education symposium for managed care professionals through an independent grant. The symposium, titled 'High-Stakes Access: Aligning Managed Care Policy with the Urgency of Treatment in Duchenne Muscular Dystrophy,' will be held on Tuesday, April 14 from 12 p.m. to 1:30 p.m. CT.

The takeaway

As Dyne Therapeutics prepares for potential launches of its neuromuscular disease treatments, the company is proactively engaging with payers to ensure access decisions reflect the meaningful benefits seen in clinical trials. This effort aims to align managed care policy with the urgency of treatment for patients living with debilitating conditions like Duchenne muscular dystrophy and myotonic dystrophy type 1.